Top

Published in:

01-12-2011 | Original Paper

Epidemiology and Natural History of Nephrolithiasis

Author: Alan G. Wasserstein

Published in: Clinical & Translational Metabolism | Issue 3-4/2011

Abstract

The epidemiology and natural history of nephrolithiasis comprise its incidence and prevalence; role of age, gender, and race; risk factors, comorbidities, and course. As such, epidemiology verges into clinical features, pathogenesis, treatment, and prognosis. Although it is well known that associations derived from epidemiological studies do not prove causal relationships, lessons from epidemiology and natural history have been readily applied to pathogenesis and treatment. Conversely, knowledge derived from experiment and interventional trials has furnished models for understanding epidemiological data. Hence, it is not easy to divide epidemiology from other aspects of nephrolithiasis. While my primary emphasis in this review will be on epidemiological studies, I will consider other kinds of studies that help us to understand the epidemiology and natural history of nephrolithiasis.

Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med. 1992;327:1141–52.PubMedCrossRef

Stamatelou KK, Francis ME, Jones CA, Nyberg LM Jr, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int. 2003;63:1817–23.PubMedCrossRef

Curhan GC. Epidemiology of stone disease. Urol Clin North Am. 2007;34:287–93.PubMedCrossRef

Soucie JM, Thun MJ, Coates RJ, McClennan W, Austin H. Demographic and geographic variability of kidney stones in the United States. Kidney Int. 1994;46:893–9.PubMedCrossRef

Ramello A, Vitale C, Marangella M. Epidemiology of nephrolithiasis. J Nephrol. 2000;13(suppl 3):S45–50.PubMed

Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol. 2010;12:e86–96.PubMed

Hesse A, Brandle E, Wilbert D, Kohrmann KU, Alken P. Study on the prevalence and incidence of urolithiasis in Germany comparing the years 1979 and 2000. Eur Urol. 2003;44:709–13.PubMedCrossRef

Akoudad S, Szklo M, McAdams MA, Fulop T, Anderson CA, Coresh J, Kottgen A. Correlates of kidney stone disease differ by race in a multi-ethnic middle aged population: the ARIC Study. Prev Med. 2010;51:416–20.PubMedCrossRef

Lieske JC, de la Pena Vega LS, Slezak JM, Bergstralh EJ, Leibson CL, Ho KL, Gettman MT. Renal stone epidemiology in Rochester, Minnesota: an update. Kidney Int. 2006;69:760–4.PubMedCrossRef

10.

Jr Scales Cd, Curtis LH, Norrias RD, Springhart P, Sur RL, Shulman KA, Preminger GM. Changing gender prevalence of stone disease. J Urol. 2007;177:979–82.PubMedCrossRef

11.

Soucie JM, Coates RJ, McClellan W, Austin H, Thun M. Relation between geographic variability in kidney stones prevalence and risk factors for stones. Am J Epid. 1996;143:487–95.

12.

Blacklock NJ. The pattern of urolithiasis in the Royal Navy. In Hodgkinson A, Nordin BE, eds. Renal stone research symposium. London:Churchill 1969;33–47.

13.

Pugliese JM, Baker KC. Epidemiology of nephrolithiasis in personnel returning fromn Operation Iraqi Freedom. Urology. 2009;74:56–61.PubMedCrossRef

14.

Parry ES, Lister IS. Sunlight and hypercalciuria. Lancet. 1975;10:1063–5.CrossRef

15.

Elomaa I, Karonen SL, Kairento AL, Pelkonen R. Seasonal variation of urinary calcium and oxalate excretion, serum 25(OH)D3 and albumin level in relation to renal stone formation. Scand J Urol Nephrol. 1982;16:155–61.PubMedCrossRef

16.

Fakheri RJ, Goldfarb D. Association of nephrolithiasis prevalence rates with ambient temperature in the United States: a re-analysis. Kidney Int. 2009;76:798.PubMedCrossRef

17.

Brikowski TH, Lotan Y, Pearle MS. Climate-related increase in the prevalence of urolithiasis in the United States. Proc Natl Acad Sci. 2008;105:9841–6.PubMedCrossRef

18.

Coe F, Keck J, Norton ER. The natural history of calcium nephrolithiasis. JAMA. 1977;238:1519–23.PubMedCrossRef

19.

Ljunghall S, Danielson BG. A prospective study of renal stone recurrences. Br J Urol. 1984;56:122–4.PubMedCrossRef

20.

Ahlstrand C, Tisleius HG. Recurrences during a 10-year follow-up after first renal stone episode. Urol Res. 1990;18:397–9.PubMedCrossRef

21.

Trinchieri A, Ostini F, Nespoli R, Rovera F, Montanari E, Zanetti G. A prospective study of recurrence rate and risk factors for recurrence after a first renal stone. J Urol. 1999;162:27–30.PubMedCrossRef

22.

Pak CY. Should patients with single renal stone occurrence undergo diagnostic evaluation? J Urol. 1982;127:855–8.PubMed

23.

Hosseini MM, Eshragian A, Dehghanian I, Irani D, Amini M. Metabolic abnormalities in patients with nephrolithiasis: comparison with of first-episode with recurrent cases in Southern Iran. Int Urol Nephrol. 2010;42:127–31.PubMedCrossRef

24.

Yagisawa T, Chandhoke PS, Fan J. Metabolic risk factors in patients with first-time and recurrent stone formations as determined by comprehensive metabolic evaluation. Urol. 1998;52:750–5.PubMedCrossRef

25.

Glowacki LS, Beecroft ML, Cook RJ, Churchill DN. The natural history of asymptomatic urolithiasis. J Urol. 1992;147:319–21.PubMed

26.

Burgher A, Beman M, Holtzman JL, Monga M. Progression of nephrolithiasis: long-term outcomes with observation of asymptomatic calculi. J Endourol. 2004;18:534–9.PubMedCrossRef

27.

Inci K, Sahin A, Islamoglu E, Eren MT, Bakkaloglu M, Ozen H. Prospective long-term followup of patients with asymptomatic lower pole caliceal stones. J Urol. 2007;177:2189–92.PubMedCrossRef

28.

Keeley FX Jr, Tilling K, Elves A, Menezes P, Wills P, Rao N, Fenely R. Preliminary results of a randomized controlled trial of prophylactic shock wave lithotripsy for small asymptomatic renal calyceal stones. B JU Int. 2001;87:1–8.

29.

Blandy JP, Singh M. The case for a more aggressive approach to staghorn stones. J Urol. 1976;115:505–6.PubMed

30.

Rous SN, Turner WR. Retrospective study of 95 patients with staghorn calculus disease. J Urol. 1977;118:902–4.PubMed

31.

Vargas AD, Bragin SD, Mendez R. Staghorn calculus: its clinical presentation, complications, and management. J Urol. 1982;127:860–2.PubMed

32.

Keoghane S, Walmsley B, Hodgson D. The natural history of untreated renal tract calculi. BJU Int. 2010;105:1627–31.PubMedCrossRef

33.

Candau C, Saussine C, Lang H, Roy C, Faure F, Jacqmin D. Natural history of residual renal stone fragments after ESWL. Eur Urol. 2000;37:18–22.PubMedCrossRef

34.

Cicerello E, Merlo F, Gambaro G, Maccatrozzo L, Fandella A, Baggio B, Anselmo G. Frammenti residui clinicamente insignificanti (CIRF) dopo litotrissia extracorporea: implicazioni e trattamento. J Urol. 1994;151:5–9.PubMed

35.

Mollerup CL, Lindewald H. Renal stones and primary hyperparathyroidism: natural history of renal stone disease after successful parathyroidectomy. World J Surg. 1999;23:173–5.PubMedCrossRef

36.

Better OS, Shabtai M, Kedar S, Melamud A, Berenheim J, Chaimovitz C. Increased incidence of nephrolithiasis in lifeguards in Israel. Adv Exp Med Biol. 1980;128:467–72.PubMed

37.

Atan L, Andreoni C, Ortiz V, Silva EK, Pitta R, Atan F, Srougi M. High kidney stone risk in men working in steel industry at hot temperatures. Urology. 2005;65:858–61.PubMedCrossRef

38.

Borghi L, Meschi T, Amato F, Novarini A, Romanelli A, Cigala F. Hot occupation and nephrolithiasis. J Urol. 1993;150:1757–60.PubMed

39.

Chauhan V, Eskin B, Allegra JR, Cochrane DG. Effect of season, age, and gender on renal colic incidence. Am J Emerg Med. 2004;22:560–3.PubMedCrossRef

40.

Cervellin G, Comelli I, Comelli D, Cortellini P, Lippi G, Meschi T, Borghi L. Regional short-term climate variations influence on the number of visits for renal colic in a large urban emergency department: results of a 7-year survey. Intern Emerg Med. 2011;6:141–7.PubMedCrossRef

41.

Baker PW, Covie P, Bais R, Rofe AM. Influence of season, age, and sex on renal stone formation in South Australia. Med J Aust. 1993;159:390–2.PubMed

42.

al-Hydramy MS. Seasonal variations of urinary stone colic in Arabia. J Pak Med Assoc. 1997;47:281–4.

43.

Vezzoli G, Terranegra A, Arcidiacono T, Soldati L. Genetics and calcium nephrolithiasis. Kidney Int 2010;epub ahead of print, Accessed 5/26/2011.

44.

Curhan GC, Willett WC, Rimm EB, Stampfer MJ. Family history and risk of kidney stones. J Am Soc Nephrol. 1997;8:1568–73.PubMed

45.

Edvardsson VO, Palsson R, Indradason OS, Thorvaldsson S, Steffanson K. Familiality of kidney stone disease in Iceland. Scand J Urol Nephrol. 2009;43:420–4.PubMedCrossRef

46.

Koyuncu H, Yencilek F, Eryildirim B, Sarica K. Family history in stone disease: how important is it for the onset of the disease and the incidence of recurrence? Urol Res. 2010;38:105–9.PubMedCrossRef

47.

Basiri A, Shakhssalim N, Khoshdel AR, Javaherforooshzadeh A, Basiri H, Radfar MH, Dorraj N. Familial relations and recurrence pattern in nephrolithiasis. Urol J. 2010;7:81–6.PubMed

48.

Coe FL, Parks JH, Moore ES. Familial idiopathic hypercalciuria. N Engl J Med. 1979;300:337–40.PubMedCrossRef

49.

Vezzoli G, Tanini A, Ferrucci L, Soldati L, Bianchin C, Franceschelli F, Malentacchi C, Porfirio B, Adamo D, Terranegra A, Falchetti A, Cusi D, Bianchi G, Brandi ML. Influence of calcium-sensing receptor gene on urinary calcium excretion in stone-forming patients. J Am Soc Nephrol. 2002;13:2517–23.PubMedCrossRef

50.

Ferreira LG, Pereira AC, Heilberg IP. Vitamin D receptor and calcium-sensing receptor gene polymorphisms in hypercalciuric stone-forming patients. Nephron Clin Pract. 2010;114:c135–44.PubMedCrossRef

51.

Thorleifsson G, Holm H, Edvardsson V, et al. Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet. 2009;412:926–30.CrossRef

52.

Torres VE, Wilson DM, Hattery RR, Segura JW. Renal stone disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1993;22:513–9.PubMed

53.

Fick GM, Gabow PA. Hereditary and acquired cystic disease of the kidney. Kidney Int. 1994;46:951–64.PubMedCrossRef

54.

Sakhaee K. Nephrolithiasis as a systemic disorder. Curr Opin Nephrol Hypertens. 2008;17:304–9.PubMedCrossRef

55.

Robertson WG, Peacock M, Baker M, Marshall DH, Pearlman B, Speed R, Sergeant V, Smith A. Studies on the prevalence and epidemiology of urinary stone disease in men in Leeds. Br J Urol. 1983;55:595–8.PubMedCrossRef

56.

Borghi L, Meschi T, Guerra A, Briganti A, Schianchi T, Allegri F, Novarini A. Essential arterial hypertension and stone disease. Kidney Int. 1999;55:2397–406.PubMedCrossRef

57.

Krambeck AE, Rule AD, Li X, Bergstrath EJ, Gettman MT, Lieske JC. Shock wave lithotripsy is not predictive of hypertension among community stone formers at long-term followup. J Urol. 2011;185:164–9.PubMedCrossRef

58.

Curhan GC, Willett WC, Rimm EB, Speizer FE, Stampfer MJ. Body size and risk of kidney stones. J Am Soc Nephrol. 1998;9:1645–52.PubMed

59.

Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA. 2005;293:455–62.PubMedCrossRef

60.

Semins M, Shore AD, Makary MA, Magnuson T, Johns R, Matiaga BR. The association of increasing body mass index and kidney stone disease. J Urol. 2010;183:571–5.PubMedCrossRef

61.

Negri AL, Spivacow FR, Del Valle EE, Forrester M, Rosende G, Pinduli I. Role of overweight and obesity on the urinary excretion of promoters and inhibitors of stone formation in stone formers. Urol Res. 2008;36:303–7.PubMedCrossRef

62.

Taylor EN, Curhan GC. Body size and 24-hour urine composition. Am J Kidney Dis. 2006;48:905–15.PubMedCrossRef

63.

Eisner BH, Eisenberg ML, Stoller ML. Relationship between body mass index and quantitative 24-hour urine chemistries in patients with nephrolithiasis. Urology. 2010;75:1289–93.PubMedCrossRef

64.

Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int. 2005;68:1230–5.PubMedCrossRef

65.

Weikert C, Weikert S, Schulze MB, Pischon T, Fritsche A, Bergmann MM, Willich SN, Boeing H. Presence of gallstones or kidney stones and risk of type 2 diabetes. Am J Epid. 2010;171:447–54.CrossRef

66.

West B, Luke A, Durazzo-Arvizo RA, Cao G, Shoham D, Kramer H. Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988–1994. Am J Kidney Dis. 2008;51:741–7.PubMedCrossRef

67.

Reiner AP, Kahn A, Eisner BH, et al. Kidney stones and subclinical atherosclorosis in young adults: the CARDIA study. J Urol. 2011;185:920–5.PubMedCrossRef

68.

DrFronzo R, Cooke CR, Andres CR, Faloona GR, Davis PJ. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest. 1975;55:845–55.CrossRef

69.

Kramer HJ, Choi HK, Atkinson K, Stampfer M, Curhan GC. The association between gout and nephrolilthiasis in men: the health professionals’ follow-up study. Kidney Int. 2003;64:1022–6.PubMedCrossRef

70.

Rule AD, Roger VL, Melton LJ III, Bergstralh EJ, Li X, Peyser PA, Krambeck AE, Lieske JC. Kidney stones associate with increased risk for myocardial infarction. J Am Soc Nephrol. 2010;21:1641–4.PubMedCrossRef

71.

Stoller ML, Meng MV, Abrahams HM, Kane JP. The primary stone event: a new hypothesis involving a vascular etiology. J Urol. 2004;171:1024–920.CrossRef

72.

Teichman JM, Long RD, Hulbert RC. Long-term renal fate and prognosis after staghorn calculus management. J Urol. 1995;153:1403–7.PubMedCrossRef

73.

Jungers P, Joly D, Barbey F, Choukroun G, Daudon M. ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am J Kidney Dis. 2004;44:799–805.PubMed

74.

Rule AD, Bergstralh EJ, Melton LJ III, Li X, Weaver AL, Lieske JC. Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:804–11.PubMedCrossRef

75.

Saucier NA, Sinha MK, Liang KV, et al. Risk factors for CKD in persons with kidney stones: a case-control study in Olmstead County, Minnesota. Am J Kidney Dis. 2010;55:61–8.PubMedCrossRef

76.

Marangella M, Bruno M, Cosseddu D, Manganaro M, Tricerri A, Vitale C, Linari F. Prevalence of chronic renal insufficiency in the course of idiopathic recurrent calcium stone disease: risk factors and patterns of progression. Nephron. 1990;54:302–6.PubMedCrossRef

77.

Sinha MK, Collazo-Clavell ML, Rule A, et al. Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. Kidney Intl. 2007;71:1000–7.

78.

Patel BN, Passman CM, Fernandez A, Asplin JR, Coe FL, Lingeman JE, Assimos DG. Prevalence of hyperoxaluria after modern bariatric surgery. J Urol. 2008;181:161–6.PubMedCrossRef

79.

Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med. 1993;328:833–8.PubMedCrossRef

80.

Curhan GC, Willett WC, Speizer FE, Spiegelman D, Stampfer MJ. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med. 1997;126:497–504.PubMed

81.

Curhan GC, Willett WC, Knight EL, Stampfer MJ. Dietary factors and the risk of incident kidney stones in younger women. Arch Intern Med. 2004;164:885–91.PubMedCrossRef

82.

Taylor EN, Stampfer MJ, Curhan GC. Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up. J Am Soc Nephrol. 2004;15:3225–532.PubMedCrossRef

83.

Taylor EN, Curhan GC. Demographic, dietary, and urinary factors and 24-h urinary calcium excretion. Clin J Am Soc Nephrol 4;1980–1987.

84.

Norman DA, Fordtran LJ, Brinkley LJ, Zerwekh JE, Nicar MJ, Strowig SM, Pak CY. Jejunal and ileal adaptation to alterations in dietary calcium: changes in calcium and magnesium absorption and pathogenetic role of parathyroid hormone and 1, 25-dihydroxyvitamin D. J Clin Invest. 1981;67:1599–603.PubMedCrossRef

85.

Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F, Maggiore U, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med. 2002;346:77–84.PubMedCrossRef

86.

Heller HJ, Doerner MF, Brinkley LJ, Adams-Huet B, Pak CY. Effect of dietary calcium on stone forming propensity. J Urol. 2003;169:470–4.PubMedCrossRef

87.

Wallace RB, Wactawski-Wende O’Sullivan MJ, Larson JC, Cochrane B, Gass M, Masaki K. Urinary tract stone occurrence in the women’s health initiative randomized clinical trial of calcium and vitamin D supplements. Am J Clin Nutr 2011; April 27 (epub ahead of print).

88.

Taylor EN, Curhan GC. Oxalate intake and the risk for nephrolithiasis. J Am Soc Nephrol. 2007;18:2198–204.PubMedCrossRef

89.

Holmes PR, Goodman HO, Assimos DG. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int. 2001;59:270–6.PubMedCrossRef

90.

Hesse A, Schneeberger W, Engfeld S, Von Unruh GE, Sauerbruch T. intestinal hyperabsorption of oxalate in calcium oxalate stone formers: application of a new test with [13C2]oxalate. J Am Soc Nephrol. 1999;2(suppl 14):S329–33.

91.

Lieske JC, Tremaine WJ, DeSimone C, O’Connor HM, Li X, Bergstralh EJ, Goldfarb D. Diet, not not oral probiotics, effectively reduces urine oxalate excretion and calcium oxalate supersaturation. Kidney Int. 2010;78:1178–11185.PubMedCrossRef

92.

Wasserstein AG. Lessons in medical humanism: the case of Montaigne. Ann Intern Med. 2007;146:809–13.PubMed

93.

Robertson WG, Heyburn PJ, Peacock M, Hanes FA, Swaminathan R. The effect of high animal protein intake on the risk of calcium stone-formation in the urinary tract. Clin Sci. 1997;9(57):285–8.

94.

Breslau NA, Brinkley L, Hill KD, Pak CY. Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism. J Clin Endocrinol Metab. 1988;66:140–6.PubMedCrossRef

95.

Robertson WG, Peacock M, Heyburn PJ, Hanes FA. Epidemiological risk factors in calcium stone disease. Scand J Urol Nephrol. 1980;53(suppl):15–30.

96.

Peacock M, Nordin BEC. Hypercalciuria of renal stone disease. In Hodgkinson, A, Nordin BEC., eds.Proceedings of the renal stone research symposium. London:Livingtons, 1969;253–261.

97.

O’Dwyer JT. Health aspects of vegetarian diets. Am J Clin Nutr. 1988;48:712–38.

98.

Wasserstein AG, Stolley PD, Soper KA, Goldfarb S, Maislin G, Agus Z. A case-control study of risk factors for idiopathic calcium nephrolithiasis. Mineral Elect Metab. 1987;13:85–95.

99.

Graces F, Costa-Bauza A. Phytate (IP6) is a powerful agent for preventing calcifications in biological fluids: usefulness in renal lithiasis treatment. Anticancer Res. 1999;19:3717–22.

100.

Graces F, Garcia-Gonzales R, Torres JJ, Llobera A. Effects of phytic acid on renal stone formation in rats. Scand J Urol Nephrol. 1998;32:261–5.CrossRef

101.

Taylor EN, Fung TT, Curhan GC. DASH-style diet associates with reduced risk for kidney stones. J Am Soc Nephrol. 2009;20:2253–9.PubMedCrossRef

102.

Taylor EN, Stampfer MJ, Mount DB, Curhan GC. DASH-style diet and 24-hour urine composition. Clin J Am Soc Nephrol. 2010;5:2315–22.PubMedCrossRef

103.

Meschi T, Maggiore U, Fiaccadori E, Schianchi T, et al. The effect of fruits and vegetables on urinary stone risk factors. Kidney Int. 2004;66:2402–10.PubMedCrossRef

104.

Taylor EN, Curhan GC. Role of nutrition in the formation of calcium-containing kidney stones. Nephron Physiol. 2004;98:55–63.CrossRef

105.

Ebisuno S, Morimoto S, Yasukawa S, Ohkawa T. Results of long-term rice bran treatment on stone recurrence in hypercalciuric patients. Br J Urol. 1991;67:237–40.PubMedCrossRef

106.

Massey LK, Whiting SJ. Dietary salt, urinary calcium, and kidney stone risk. Nutr Rev. 1995;53:131–9.PubMedCrossRef

107.

Sakhaee K, Harvey JA, Padalino PK, Whitson P, Pak CY. The potential role of salt abuse on the risk for kidney stone formation. J Urol. 1993;150:310–2.PubMed

108.

Stoller ML, Chi T, Eisner BH, et al. Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation. J Urol. 2009;181:1140.PubMedCrossRef

109.

Eisner BH, Eisenberg ML, Stoller ML. Impact of urine sodium on urine risk factors for calcium oxalate nephrolithiasis. J Urol. 2009;182:2330–3.PubMedCrossRef

110.

Yun SJ, Ha YS, Kim WT, et al. Sodium restriction as initial conservative treatment for urinary stone disease. J Urol. 2010;184:1372–6.PubMedCrossRef

111.

Nouvenne A, Meschi T, Prati B, Guerra A, et al. Effects of a low-salt diet on idiopathic hypercalciuria in calcium-oxalate stone formers: a 3-mo randomized controlled trial. Am J Clin Nutr. 2010;91:565–70.PubMedCrossRef

112.

Thom JA, Morris JE, Bishop A, Blacklock NJ. The influence of refined carbohydrate on urinary calcium excretion. Br J Urol. 1978;50:459–64.PubMedCrossRef

113.

Iguchi M, Umekawa T, Takamura C, et al. Glucose metabolism in renal stone patients. Urol Int. 1993;51:185–90.PubMedCrossRef

114.

Power C, Barker DJ, Nelson M, Winter PD. Diet and renal stones: a case-control study. Br J Urol. 1984;56:456–9.PubMed

115.

Knight J, Assimos DG, Easter L, Holmes RP. Metabolism of fructose to oxalate and glycolate. Hormone Metab Res. 2010;42:868–73.CrossRef

116.

Curhan GC, Willett WC, Rimm EB, Spiegelman D, Stampfer MJ. Prospective study of beverage use and the risk of kidney stones. Am J Epidemiol. 1996;143:240–7.PubMed

117.

Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Beverage use and risk for kidney stones in women. Ann Intern Med. 1998;128:534–40.PubMed

118.

Borghi L, Meschi T, Amato F, et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol. 1996;155:839–43.PubMedCrossRef

119.

Honow R, Laube N, Schneider A, Kessler T, Hesse A. Influence of grapefruit-, orange- and apple-juice consumption on urinary variables and risk of crystallization. Br J Nutr. 2003;90:295–300.PubMedCrossRef

120.

Trinchieri A, Lizzano R, Bernardini P, et al. Effect of acute load of grapefruit juice on urinary excretion of citrate and urinary risk factors for renal stone formation. Dig Liver Dis. 2002;34(Suppl 2):S160–3.PubMedCrossRef

121.

Shuster J, Finlayson B, Scheaffer RL, Sierakowski R, Zoltek J, Dzegede S. Primary liquid intake and urinary stone disease. J Chron Dis. 1985;38:907–14.PubMedCrossRef

122.

Shuster J, Jenkins A, Logan C, et al. Soft drink consumption and urinary stone recurrence: a randomized prevention trial. J Clin Epidemiol. 1992;45:911–6.PubMedCrossRef

123.

Sweeney DD, Tomaszewski JJ, Ricchiuti DD, Averch T. Effect of carbohydrate-electrolyte sports beverages on urinary stone risk factors. J Urol. 2009;182:992–7.PubMedCrossRef

124.

Penniston KL, Steele TH, Nakada SY. Lemonade therapy increases urinary citrate and urine volumes in paitents with recurrent calcium oxalate stone formation. Urology. 2007;70:856–60.PubMedCrossRef

125.

Koff SG, Paquette EL, Cullen J, et al. Comparison between lemonade and potassium citrate and impact on urine pH and 24-hour urine parameters in patients with kidney stone formation. Urology. 2007;69:1013–6.PubMedCrossRef

126.

Odvina CV. Comparative value of orange juice versus lemonade in reducing stone-forming risk. Clin J Am Soc Nephrol. 2006;1:1269–74.PubMedCrossRef

127.

Taylor EN, Stampfer MJ, Curhan GC. Fatty acid intake and incident nephrolithiasis. Am J Kidney Dis. 2005;45:267–74.PubMedCrossRef

128.

Urivetzky M, Kessaris D, Smith AD. Ascorbic acid overdosing: a risk factor for calcium oxalate nephrolithiasis. J Urol. 1992;147:1215–8.PubMed

129.

Robitaille L, Marner OA, Miller WH Jr, et al. Oxalic acid excretion after intravenous ascorbic acid administration. Metabolism. 2009;58:263–9.PubMedCrossRef

130.

Curhan GC, Willett W, Rimm E, Stampfer MJ. A prospective study of the intake of vitamin C and vitamin B6 and the risk of kidney stones in men. J Urol. 1996;155:1847–51.PubMedCrossRef

131.

Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Intake of vitamins B6 and C and the risk of kidney stones in women. J Am Soc Nephrol. 1999;10:840–5.PubMed

132.

Penniston KL, Jones AN, Nakada SY, Hansen KE. Vitamin D repletion does not alter urinary calcium excretion in healthy postmenopausal women. BJU Int. 2009;104:1512–6.PubMedCrossRef

133.

Hodgkinson A, Pyrah LN. The urinary excretion of calcium and inorganic phosphate in 344 patients with calcium stone of renal origin. Br J Surg. 1958;48:10–8.CrossRef

134.

Coe FL. Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder. Ann Intern Med. 1977;87:404–10.PubMed

135.

Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Twenty-four-hour urine chemistries and the risk of kidney stones among men and women. Kidney Int. 2001;59:2290–8.PubMed

136.

Worcester EM, Coe FL. New insights into the pathogenesis of idiopathic hypercalciuria. Sem Nephrol. 2008;28:120–32.CrossRef

137.

Taylor EN, Curhan GC. Demographic, dietary, and urinary factors and 24-h urinary calcium excretion. Clin J Am Soc Nephrol. 2009;4:1980–7.PubMedCrossRef

138.

Kaufman DW, Kelly JP, Curhan GC, et al. Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol. 2008;19:1197–203.PubMedCrossRef

139.

Taylor EN, Curhan GC. Determinants of 24-hour urinary oxalate excretion. Clin J Am Soc Nephrol. 2008;3:1453–60.PubMedCrossRef

140.

Goldberg H, Grass L, Vogl R, Rapoport A, Oreopoulos DG. Urinary citrate and renal stone disease. CMAJ. 1989;141(3):217–21.PubMed

141.

Ettinger B, Tang A, Citron JT, et al. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med. 1986;315:1386–9.PubMedCrossRef

142.

Matiaga BR, Schaeffer AJ, Novak TE, Trock BJ. Epidemiologic insights into pediatric kidney stone disease. Urol Res. 2010;38:453–7.CrossRef

143.

Spivacow FR, Negri AL, del Valle EE, et al. Metabolic risk factors in children with kidney stone disease. Pediatr Nephrol. 2008;23:1129–33.PubMedCrossRef

144.

VanDervoort K, Wiesen J, Frank R, et al. Urolithiasis in pediatric patients: a single center study of incidence, clinical presentation and outcome. J Urol. 2007;177:2300–5.PubMedCrossRef

145.

Sas DJ, Hulsey TC, Shatat IF, Orak JK. Increasing incidence of kidney stones in children evaluated in the emergency department. J Pediatr. 2010;157:32–137.CrossRef

146.

Kalorin CM, Zabinski A, Okpareke I, et al. Pediatric stone disease–does age matter? J Urol. 2009;181:2267–71.PubMedCrossRef

147.

Pietrow PK, Pope JCIV, Adams MC, et al. Clinical outcome of pediatric stone disease. J Urol. 2002;167:670–3.PubMedCrossRef

148.

DeFoor WR, Jackson E, Minevich E, et al. The risk of recurrent urolithiasis in children is dependent on urinary calcium and citrate. Urology. 2010;76:242–5.PubMedCrossRef

149.

Alaya A, Nouri A, Najjar MF. Changes in stone composition according to age and gender in Tunisian children. J Ped Urol. 2010;6:364–71.CrossRef

150.

Erbaqci A, Erbaqci B, Yilmaz M, et al. Pediatric urolithiasis–evaluation of risk factors in 95 children. Scand J Urol Nephrol. 2003;37:129–33.CrossRef

151.

Acar B, Inci Arakan F, Emeksiz S, Dallar Y. Risk factors for nephrolithiasis in children. World J Urol. 2008;26:627–30.PubMedCrossRef

152.

Schaeffer AJ, Feng Z, Trock BJ, et al. Medical comorbidities associated with pediatric stone disease. Urology. 2011;77:195–9.PubMedCrossRef

153.

Schwaderer AL, Cronin R, Mahan JD, Bates CM. Low bone density in children with hypercalciuria and/or nephrolithiasis. Pediatr Nephrol. 2008;23:2209–14.PubMedCrossRef

Title: Epidemiology and Natural History of Nephrolithiasis
Author: Alan G. Wasserstein
Publication date: 01-12-2011
Publisher: Springer-Verlag
Published in: Clinical & Translational Metabolism / Issue 3-4/2011
Print ISSN: 1534-8644
Electronic ISSN: 2948-2445
DOI: https://doi.org/10.1007/s12018-011-9097-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3-4/2011

Clinical Presentation of Nephrolithiasis

Mechanisms of Stone Formation

Miscellaneous Stone Types

Calcium Nephrolithiasis

Introduction

Uric Acid Nephrolithiasis: A Systemic Metabolic Disorder

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials